Halvor Næss

Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial

Nicola Logallo, Vojtěch Novotný, Christopher Elnan Kvistad et al. · The Lancet Neurology · 2017 · 458 citations

Thrombosis, Endpoint Trial, Tenecteplase Versus Alteplase +13

Benefit from B-Lymphocyte Depletion Using the Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome. A Double-Blind and Placebo-Controlled Study

Øystein Fluge, Ove Bruland, Kristin Risa et al. · PLoS ONE · 2011 · 196 citations · Full text

Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial

Christopher Elnan Kvistad, Halvor Næss, Bernt Harald Helleberg et al. · The Lancet Neurology · 2022 · 191 citations

Thrombosis, Tenecteplase Versus Alteplase, Cardiovascular Disease +15

Associations between post-stroke motor and cognitive function: a cross-sectional study

Marte Stine Einstad, Ingvild Saltvedt, Stian Lydersen et al. · BMC Geriatrics · 2021 · 172 citations · Full text

Recurrent ischemic stroke: Incidence, predictors, and impact on mortality

Andrej Netland Khanevski, Anna Therese Bjerkreim, Vojtěch Novotný et al. · Acta Neurologica Scandinavica · 2019 · 168 citations · Full text